GSK3B and early-onset autosomal dominant Alzheimer disease: All these data suggest the potential use of this site‐specific inhibitor of GSK‐3β as a helpful tool for the treatment of brain/mental/psychiatric diseases that depend on GSK‐3β activation, such as mood disorders, or even neurodegenerative diseases such as tauopathies and Alzheimer's disease.